The Science of Thermoregulation and Vasomotor Symptoms: Possible New Targets for

体温调节和血管舒缩症状的科学：可能的新目标

• 批准号: 8784849
• 负责人: PAULINE M MAKI
• 金额: $ 4.64万
• 依托单位: UNIVERSITY OF ILLINOIS AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-08-15 至 2016-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8784849
• 关键词: Address; Aging; American; Antidepressive Agents; Area; Award; Basic Science; Cancer Survivor; Cardiovascular system; Clinical; Clinical Research; Cognitive; Complementary and alternative medicine; Consensus; Data; Development; District of Columbia; Dose; Etiology; Exercise; Exercise Physiology; FDA approved; Funding; Goals; Health; Homeostasis; Hot flushes; Journals; Knowledge; Link; Medical; Medicine; Menopausal Symptom; Menopause; Meta-Analysis; National Institute on Aging; Neurobiology; Neuropharmacology; Night Sweating; North America; Omega-3 Fatty Acids; Oral; Outcome; Paroxetine; Participant; Pathway interactions; Pharmaceutical Preparations; Physiologic Thermoregulation; Physiology; Professional Organizations; Publications; Publishing; Quality of life; Randomized Clinical Trials; Recommendation; Research; Research Personnel; Research Priority; Resources; Science; Scientific Advances and Accomplishments; Scientist; Secure; Selective Serotonin Reuptake Inhibitor; Seminal; Skin; Societies; Staging; Symptoms; Temperature; Travel; United States National Institutes of Health; Vasomotor; Woman; Women' s Health; Work; Yoga; base; clinical efficacy; cognitive function; depressive symptoms; drug development; experience; healthy aging; hormone therapy; innovation; meetings; middle age; multidisciplinary; neuroimaging; neurophysiology; new therapeutic target; posters; pre-clinical research; programs; public health relevance; randomized trial; reproductive; standard care; success; symposium; web site; working group

DESCRIPTION (provided by applicant): More than 80% of women experience vasomotor symptoms (VMS; hot flashes and night sweats) during the menopausal transition. The use of hormone therapy, the standard treatment for VMS, decreased by 75% after publication of the findings from the Women's Health Initiative. The only FDA-approved nonhormonal treatment for VMS is paroxetine, a low-dose antidepressant that showed significant but modest efficacy in randomized trials. In the past decade, our understanding of the efficacy of nonhormonal therapies on VMS has increased considerably based on findings from randomized clinical trials. Unfortunately, the results from these trials show no-to-minimal efficacy, and two nonhormonal VMS medications recently failed to win FDA approval. Women therefore have very few nonhormonal treatment options for VMS. To address the continuing need for development of new nonhormonal therapies for VMS, we propose a multidisciplinary, 2-day conference, The Science of Thermoregulation and Vasomotor Symptoms: Possible New Targets for Treatment. The conference will convene a diverse group of 20 to 25 basic and clinical researchers as well as clinicians to discuss normal and aberrant thermoregulation, the neurophysiology of VMS, and new potential treatment targets. The aim of the conference is to facilitate synthesis and exchange of new data by promoting scientific exchange among experts who do not typically interact scientifically but whose work informs the others. In recent years, scientific understanding of the mechanisms involved in VMS has evolved considerably based on findings from basic science, physiology, neuroimaging, and studies of skin dynamics. The specific aims are to 1) describe current understanding of the physiology and neuropharmacology of thermoregulation and VMS; 2) describe current understanding of nonhormonal treatments for VMS; 3) review existing evidence from studies linking VMS to adverse health outcomes in women, including quality of life, cardiovascular outcomes, and cognitive function; 4) integrate new and emerging data from multiple areas of inquiry into an initial conceptual framework to better understand the causal pathway of VMS and potential avenues for new drug development. The Day 1 public symposium, open to 80 participants, will feature oral and poster presentations of recent scientific advances in thermoregulation and VMS and discussion of the implications of this new evidence for the development of nonhormonal VMS treatments. On Day 2, facilitated working groups will discuss and respond to targeted questions regarding research priorities. We offer four travel awards for new investigators. The meeting will be sponsored by The North American Menopause Society (NAMS) and will take place October 14-15, 2014, just before the 25th NAMS Annual Meeting in Washington, DC. The symposium recommendations will be presented in a special session at the NAMS meeting. A Program Planning Committee will prepare a conference summary for oral presentation at the NAMS Annual Meeting, an executive summary of the recommendations for publication in the official NAMS journal, Menopause, and a lay version to be published on the NAMS website.

描述（由申请人提供）：超过80％的女性经历了更年期过渡期间的血管舒适症状（VMS；潮热和夜间汗水）。在妇女健康计划中发表了发现结果后，使用激素治疗是VM的标准治疗，对VM的标准治疗方法降低了75％。 VMS的唯一FDA批准的非激素治疗是帕罗西汀，帕罗西汀是一种低剂量抗抑郁药，在随机试验中显示出明显但适度的疗效。在过去的十年中，根据随机临床试验的发现，我们对非激素疗法对VM的功效的理解已大大增加。不幸的是，这些试验的结果表明没有到最小的疗效，两种非激素VMS药物最近未能赢得FDA批准。因此，女性对VM的非激素治疗方案很少。为了满足对VM的新非激素疗法开发的持续需求，我们提出了一个多学科的2天会议，“体温调节科学和血管舒缩症状科学：可能的治疗目标”。该会议将召集一个由20至25名基础研究人员和临床医生组成的多样化组，讨论正常和异常的体温调节，VM的神经生理学以及新的潜在治疗靶标。会议的目的是通过促进通常不科学互动但工作依据的专家之间的科学交流来促进新数据的综合和交流。近年来，基于基础科学，生理学，神经影像学和皮肤动力学研究的发现，对涉及VM中涉及机制的科学理解已经大大发展。具体目的是1）描述当前对体温调节和VM的生理学和神经药理的理解； 2）描述当前对VM的非激素治疗的理解； 3）回顾了将VM与女性不良健康结果联系起来的现有证据，包括生活质量，心血管结局和认知功能； 4）将来自多个查询领域的新数据和新兴数据整合到一个初始概念框架中，以更好地了解VM的因果途径和新药物开发的潜在途径。第1天的公开研讨会向80名参与者开放，将以口头和海报的介绍，介绍热调节和VM的最新科学进步，并讨论了这一新证据对发展非激素VMS治疗的含义。在第2天，便利的工作组将讨论并回答有关研究重点的有针对性问题。我们为新调查人员提供四个旅行奖。会议将由北美更年期协会（NAMS）赞助，并将于2014年10月14日至15日举行，就在华盛顿特区第25届NAMS年度会议之前。研讨会的建议将在NAMS会议上的特别会议上提出。计划计划委员会将在NAMS年度会议上准备口头介绍的会议摘要，《 NAMS官方杂志》，《更年期》和《外行版本》在NAMS网站上发布的发表建议的执行摘要。